Occam Places Steve Staben as CSO at Lycia Therapeutics
Lycia Therapeutics, Inc., a leader in extracellular protein degradation has appointed Steve Staben, Ph.D., as Chief Scientific Officer. Prior to joining Lycia, Dr. Staben spent over 14 years at Genentech leading drug discovery programs in oncology and immunology as well as new modality platforms.
Steve has co-authored over 70 peer-reviewed articles and patent applications and holds his Ph.D. in organic chemistry from the University of California, Berkeley.
Occam Global is an executive recruiting and leadership advisory firm with specialties across technological fields including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.